The GLP-1 Price War Has Arrived. Eli Lilly Is Crushing Novo Nordisk.
Novo Nordisk just cut US list prices on Ozempic and Wegovy by up to 50%. Eli Lilly's oral pill is on shelves. The duopoly is over — and the real trade is the second-order book.
A 50% price cut. A new oral pill. And Novo Nordisk losing share for the first time in a decade.
The most successful drug class in pharmaceutical history just entered its ugliest phase. On February 24, Novo Nordisk announced it would slash US list prices on Wegovy, Ozempic, and Rybelsus by up to 50% — effective January 1, 2027. Wegovy's wholesale price drops from roughly $1,350 a month to $675. Ozempic falls about 35%.
This is not a discount. It is a surrender.
For three years, Novo Nordisk and Eli Lilly carved up the obesity and diabetes market between them with near-monopoly pricing. The two stocks rallied together. Analysts treated them as joint beneficiaries of the same secular tailwind. That arrangement is over.
In April, the FDA approved Lilly's Foundayo (orforglipron) — the first oral GLP-1 pill that can be taken any time of day, no food or water restrictions, no refrigeration. It launched on LillyDirect within a week. Trial data showed about 12–13% body-weight loss on the highest dose. The retail price for the lowest dose started around $149 a month. Novo's competing oral semaglutide came to market in the same window but landed with less commercial momentum and a less convenient label.
Layer on top: the Trump administration's November 2025 deal with both companies. Through TrumpRx.gov, launched January 2026, cash-pay injectables landed around $350 a month, with Medicare/Medicaid pathways pushing prices toward $245. Medicare Part D coverage for obesity indications is opening mid-2026.
The result: a market that was supposed to grow to $150 billion by 2030 on premium pricing is now growing on volume — and Lilly is winning the volume war.
The scoreboard
Lilly's tirzepatide franchise (Mounjaro and Zepbound) overtook Novo's semaglutide franchise (Ozempic and Wegovy) in US new-prescription share during Q1 2026. Lilly is guiding to roughly 25% sales growth this year. Novo is guiding to a 5–13% decline in sales and profit — its first negative year since the GLP-1 boom began.
Novo's problems are compounding:
- Loss of exclusivity in China, Brazil, and Canada is pulling international revenue down. Cost-plus modeling suggests generic semaglutide can be produced for $28–$140 per patient per year outside the US. That number alone reframes the long-term pricing floor.
- Compounded semaglutide in the US has not gone away. The 503A and 503B carve-outs continue to siphon cash-pay patients, even as the FDA tightens enforcement.
- Pipeline gap: Novo's CagriSema disappointed on weight loss versus expectations. Lilly's retatrutide is showing 20%+ weight loss in Phase 3. The next generation is not a tie.
For investors who treated Novo as a defensive growth name, the chart since November tells the story. The setup from here is what matters.
This is where the analysis gets actionable. AlphaBriefing members get the full investment framework — scenarios, positioning, and the bottom line.
Subscribe to AlphaBriefing — Free, Member, and Paid tiers available.